MedBodh Research & Clinical Guidelines | 29 October 2026 | WHO report dated 26 October; update 28 October 2026
The World Health Organization has published Target regimen profiles for long-acting injectables for tuberculosis prevention and treatment, an 85-page research-development document. Its objective is to clarify what future injectable tuberculosis (TB) regimens should achieve to offer meaningful advantages over existing oral regimens. It does not announce a licensed injectable TB regimen or authorize healthcare workers to replace current standard TB treatment.
Why researchers are considering long-acting injectables
Current TB prevention and disease treatment often require oral drugs over prolonged periods. Treatment burden, adverse effects, travel, stigma and interruptions can complicate sustained adherence. Long-acting formulations could reduce pill-taking frequency; however, fewer injections are not necessarily easier for patients if they increase clinic visits, injection reactions, costs or barriers to follow-up. The WHO profiles therefore explicitly consider the patient and health-system perspective.
WHO’s two distinct target profiles
| Target area | Aspirational WHO regimen characteristic | Important qualifier |
|---|---|---|
| TB preventive treatment | A complete preventive course in one injection encounter | Development target; not a current routine regimen |
| TB disease treatment | Regimen of no more than four months in three or fewer dosing encounters | Candidate still needs clinical trials demonstrating efficacy and safety |
| Delivery setting | Trained health worker at lowest feasible health-system level | Not an authorization for unsupervised community injections |
| Product properties | Small injection volumes and no cold-chain requirement | Design goals, not attributes of an available medicine |
| Outcomes | Efficacy and safety at least as good as current oral regimens | Must be demonstrated in relevant populations |
What must be proved before practice changes?
- Clinical outcomes: Prevention of active TB or durable cure, with relapse monitoring—not merely blood drug levels.
- Resistance and pharmacokinetics: Adequate exposure throughout the dosing interval; assessment of prolonged subtherapeutic tails and possible drug resistance.
- Safety: Local injection reactions, systemic adverse events, interactions, pregnancy and other special populations where data permit.
- Operational feasibility: Sterile administration, pharmacovigilance, supply-chain quality, training and timely follow-up.
- Patient choice: Transparent comparison with effective oral alternatives; a patient who prefers tablets should not be compelled to receive injections solely because they are long acting.
Practical relevance to Indian NTEP and CHCs
For now, CHC teams should continue to use current National TB Elimination Programme algorithms for TB diagnosis, drug-susceptibility evaluation, preventive treatment, directly supported adherence and referral. An investigational profile is not a new NTEP operational circular. If a genuine trial becomes available, enrolment must occur only through appropriate approved clinical-research pathways, informed consent and site protocols.
Clinical takeaway
WHO is encouraging development of simpler future options without compromising efficacy, safety, affordability or equitable access. The key story is a research roadmap, not an injectable cure already on pharmacy shelves.
Primary references
- WHO target regimen profiles, 26 October 2026
- WHO news update, 28 October 2026
- India’s Central TB Division / NTEP official site
Editorial safety notice: No injection dosage, procurement advice or off-label substitution is recommended here.